170 related articles for article (PubMed ID: 35220324)
1. Preferentially Expressed Nuclear Antigen in Melanoma Expression in Melanocytic Activation (Melanotic Macule) of the Nail Unit. A Potential Diagnostic Pitfall? A Study of 3 Cases.
Perrin C
Am J Dermatopathol; 2022 Jul; 44(7):499-502. PubMed ID: 35220324
[TBL] [Abstract][Full Text] [Related]
2. PRAME expression in melanocytic lesions of the nail.
Parra O; Linos K; Li Z; Yan S
J Cutan Pathol; 2022 Jul; 49(7):610-617. PubMed ID: 35294053
[TBL] [Abstract][Full Text] [Related]
3. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
4. Comparative Analysis of PRAME Expression in 127 Acral and Nail Melanocytic Lesions.
Santandrea G; Valli R; Zanetti E; Ragazzi M; Pampena R; Longo C; Lai M; Piana S; Cesinaro AM
Am J Surg Pathol; 2022 May; 46(5):579-590. PubMed ID: 35275883
[TBL] [Abstract][Full Text] [Related]
5. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
Googe PB; Flanigan KL; Miedema JR
Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
[TBL] [Abstract][Full Text] [Related]
6. Melanocytes Pattern in the Normal Nail, With Special Reference to Nail Bed Melanocytes.
Perrin C; Michiels JF; Boyer J; Ambrosetti D
Am J Dermatopathol; 2018 Mar; 40(3):180-184. PubMed ID: 28692464
[TBL] [Abstract][Full Text] [Related]
7. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
[TBL] [Abstract][Full Text] [Related]
8. The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors.
Alomari AK; Tharp AW; Umphress B; Kowal RP
J Cutan Pathol; 2021 Sep; 48(9):1115-1123. PubMed ID: 33660310
[TBL] [Abstract][Full Text] [Related]
9. The utility of PRAME staining in identifying malignant transformation of melanocytic nevi.
Lohman ME; Steen AJ; Grekin RC; North JP
J Cutan Pathol; 2021 Jul; 48(7):856-862. PubMed ID: 33433032
[TBL] [Abstract][Full Text] [Related]
10. Preferentially expressed antigen in melanoma expression in nonmelanoma skin cancers and melanocytes in surrounding skin.
Elsensohn A; Hanson J; Ferringer T
J Cutan Pathol; 2021 Sep; 48(9):1150-1155. PubMed ID: 33719089
[TBL] [Abstract][Full Text] [Related]
11. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms.
McBride JD; McAfee JL; Piliang M; Bergfeld WF; Fernandez AP; Ronen S; Billings SD; Ko JS
J Cutan Pathol; 2022 Mar; 49(3):220-230. PubMed ID: 34476825
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry for Preferentially Expressed Antigen in Melanoma in the Differential Diagnosis of Melanocytic Lesions of the Nail Apparatus.
Krajisnik A; Gharavi NM; Faries MB; Balzer BL; Frishberg DP; Martelli M; Shon W
Am J Dermatopathol; 2022 Jul; 44(7):488-492. PubMed ID: 35120028
[TBL] [Abstract][Full Text] [Related]
13. Histologic distinction between subungual lentigo and melanoma.
Amin B; Nehal KS; Jungbluth AA; Zaidi B; Brady MS; Coit DC; Zhou Q; Busam KJ
Am J Surg Pathol; 2008 Jun; 32(6):835-43. PubMed ID: 18391745
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical characterization of benign activation of junctional melanocytes and melanoma in situ of the nail unit.
Chu A; André J; Rich P; Leachman S; Thompson CT
J Cutan Pathol; 2019 Jul; 46(7):479-483. PubMed ID: 30887559
[TBL] [Abstract][Full Text] [Related]
15. Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature Review.
Turner N; Ko CJ; McNiff JM; Galan A
Am J Dermatopathol; 2024 Jan; 46(1):21-30. PubMed ID: 37982498
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1 and PRAME expression in distinguishing melanoma in situ from benign melanocytic proliferation of the nail unit.
Kim YJ; Jung CJ; Na H; Lee WJ; Chang SE; Lee MW; Park CS; Lim Y; Won CH
Diagn Pathol; 2022 Apr; 17(1):41. PubMed ID: 35484605
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Melanocyte-Associated Immunohistochemical Markers in Acral Lentiginous Melanoma and Acral Benign Nevi.
Kim JC; Choi JW; Kim YC
Am J Dermatopathol; 2023 Nov; 45(11):748-752. PubMed ID: 37856738
[TBL] [Abstract][Full Text] [Related]
18. Expression of Melan-A in cutaneous granular cell tumours: a diagnostic pitfall.
Van Winden VI; Wong DD; Wood BA; Filion P; Harvey NT
Pathology; 2024 Feb; 56(1):47-51. PubMed ID: 37989630
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of PRAME expression by immunohistochemistry in subungual and non-subungual acral melanocytic lesions.
Rothrock AT; Torres-Cabala CA; Milton DR; Cho WC; Nagarajan P; Vanderbeck K; Curry JL; Ivan D; Prieto VG; Aung PP
J Cutan Pathol; 2022 Oct; 49(10):859-867. PubMed ID: 35794643
[TBL] [Abstract][Full Text] [Related]
20. PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer.
Cassalia F; Danese A; Tudurachi I; Federico S; Zambello A; Guidotti A; Franceschin L; Bolzon A; Naldi L; Belloni Fortina A
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
